The FDA has granted approval to Astellas Pharma’s Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. Izervay, a novel complement C5 inhibitor, is now the sole approved treatment for GA with a statistically significant reduction in GA progression demonstrated in two Phase III clinical trials. With an estimated 1.5 million people affected by GA in the US and a substantial risk of blindness without timely treatment, this approval represents a significant advancement in the treatment of this condition. Izervay‘s availability offers new hope to patients and has the potential to transform lives by preserving vision and reducing the burden of visual impairment caused by GA.

If you’re interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales.